Seminars in Immunology最新文献

A framework for the rational design of oncolytic viruses: A holistic perspective considering the tumour microenvironment 溶瘤病毒合理设计的框架：考虑肿瘤微环境的整体视角

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-06-25 DOI: 10.1016/j.smim.2025.101977

Dylan Thomas , Priya Bharadwa , Timothy Lee , Carolina S. Ilkow

{"title":"A framework for the rational design of oncolytic viruses: A holistic perspective considering the tumour microenvironment","authors":"Dylan Thomas , Priya Bharadwa , Timothy Lee , Carolina S. Ilkow","doi":"10.1016/j.smim.2025.101977","DOIUrl":"10.1016/j.smim.2025.101977","url":null,"abstract":"<div><div>Oncolytic viruses have played a pioneering role in establishing immunotherapies as the next generation of anti-cancer medicines. Recent works have highlighted the impact the tumour microenvironment has on the efficacy of immunotherapies like oncolytic viruses, as well as the ability of oncolytic viruses to modulate and reconfigure this microenvironment. Within this review, we examine the vast and increasing evidence highlighting the pivotal role of tumour microenvironment in dictating oncolytic virotherapy efficacy, while also discussing potential avenues for the future development of oncolytic viruses. Following introductions to commonly used oncolytic viruses and components of the tumour microenvironment, we highlight recent research investigating their reciprocal relationships. Finally, innovations in 3D modelling to reconstitute the tumour microenvironment <em>ex vivo</em> are discussed, followed by examination of successful case studies in which tumour microenvironment dynamics have informed the rational design of successful and tailored oncolytic viruses. Through this, we provide evidence that substantial tumour heterogeneity amongst patients and tumour types significantly impedes effective oncolytic virotherapy, thus we suggest that consideration of each unique tumour microenvironment’s dynamics is critical for the design of functional and efficacious oncolytic virotherapy – both as a monotherapy or in combination with other cancer therapies.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101977"},"PeriodicalIF":7.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Local and Cell-intrinsic complement: The new player in cancer progression 局部和细胞内在补体：癌症进展的新参与者

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-06-24 DOI: 10.1016/j.smim.2025.101976

M. Revel , N.S. Merle

{"title":"Local and Cell-intrinsic complement: The new player in cancer progression","authors":"M. Revel , N.S. Merle","doi":"10.1016/j.smim.2025.101976","DOIUrl":"10.1016/j.smim.2025.101976","url":null,"abstract":"<div><div>The complement system, a key component of innate immunity, has a paradoxical role in cancer, acting both as a tumor suppressor and a promoter. While traditionally recognized for its extracellular immune functions, recent discoveries highlight non-canonical, intracellular roles in tumor progression. These findings challenge the conventional view that complement activity is confined to the extracellular space and reveal its unexpected influence on tumor proliferation, immune evasion, and metastasis. Tumors exploit local complement activation to create an immunosuppressive microenvironment, often upregulating regulatory proteins to evade complement-mediated cytotoxicity. Complement proteins can also promote tumor growth and therapy resistance through extracellular signaling and intracellular interactions with oncogenic pathways. The emerging concept of an intracellular complement system, or \"complosome,\" further suggests roles in cell metabolism, immune modulation, and stress responses. Despite these insights, key challenges remain in defining cell-specific complement functions and distinguishing autocrine, paracrine, and intracellular signaling. Current studies rely heavily on gene expression data, which do not fully reflect protein activity. Advances in gene editing, single-cell technologies, and intracellular complement inhibitors will be critical for clarifying the complex roles of complement in cancer and identifying new therapeutic strategies.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101976"},"PeriodicalIF":7.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic virus-mediated immunomodulation in glioblastoma: Insights from clinical trials and challenges 胶质母细胞瘤中溶瘤病毒介导的免疫调节：来自临床试验和挑战的见解

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-06-23 DOI: 10.1016/j.smim.2025.101975

Raziye Piranlioglu , E. Antonio Chiocca

{"title":"Oncolytic virus-mediated immunomodulation in glioblastoma: Insights from clinical trials and challenges","authors":"Raziye Piranlioglu , E. Antonio Chiocca","doi":"10.1016/j.smim.2025.101975","DOIUrl":"10.1016/j.smim.2025.101975","url":null,"abstract":"<div><div>The pivotal involvement of the host immune system in cancer therapy has dramatically reshaped therapeutic paradigms, inaugurating the era of immunotherapy. Nonetheless, antigen-specific immunotherapies encounter substantial hurdles within the highly immunosuppressive microenvironment of glioblastoma (GBM), which thwarts antitumor T-cell immunity. Oncolytic viruses (OVs), a form of immunotherapy that inflames the GBM microenvironment, have been subject to clinical evaluation, yielding promising outcomes. Evidence increasingly indicates that OVs can modify the GBM microenvironment from an immunosuppressive to an immune active state, facilitating enhanced antitumor responses. Clinical trials demonstrate that oncolytic virotherapy is generally well-tolerated, generating data about its immune-activating effects. \"Window of opportunity\" trials provide insights into viral replication, pre-existing immunity, and delivery methods. However, constraints in post-treatment sampling may impede comprehensive analyses of the virotherapy-induced biological and immunological changes. This review discusses current advancements and persistent challenges in GBM trials involving OVs.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101975"},"PeriodicalIF":7.4,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evolutionary perspective of the roles of galectins in pathogen recognition and immunity 凝集素在病原体识别和免疫中的作用的进化观点

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-06-16 DOI: 10.1016/j.smim.2025.101974

Gerardo R. Vasta , Gabriel A. Rabinovich

{"title":"An evolutionary perspective of the roles of galectins in pathogen recognition and immunity","authors":"Gerardo R. Vasta , Gabriel A. Rabinovich","doi":"10.1016/j.smim.2025.101974","DOIUrl":"10.1016/j.smim.2025.101974","url":null,"abstract":"<div><div>Protein-glycan interactions, mediated by lectins, are essential for diverse physiological processes, including glycoprotein processing, cell adhesion, communication, signaling, and immune recognition. Lectins, classified into families like C-type, I-type, F-type, and galectins, recognize specific glycans on macromolecules through their carbohydrate recognition domains (CRDs). Galectins, characterized by their β-galactoside binding and conserved CRD structure, exhibit remarkable functional diversification across evolution. Initially associated with developmental roles, they are now implicated in cancer, angiogenesis, and immune homeostasis. Furthermore, they interact with glycans on both beneficial and pathogenic microorganisms. While host galectins facilitate mutualistic interactions, pathogens can exploit this recognition for infection and manipulate host glycosylation to subvert galectin functions. The ability of galectins to recognize both self and non-self glycans, evident even in early metazoans, underscores their evolutionary versatility and raises questions about their primordial function and their evolutionary trajectory<strong>.</strong> This review explores the evolving roles of galectins, highlighting their adaptability and the complex interplay between host and pathogen interactions.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101974"},"PeriodicalIF":7.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144298566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The glycoimmune landscape in health and disease 健康和疾病中的糖免疫景观

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-05-20 DOI: 10.1016/j.smim.2025.101965

Salomé S. Pinho , Gabriel A. Rabinovich

{"title":"The glycoimmune landscape in health and disease","authors":"Salomé S. Pinho , Gabriel A. Rabinovich","doi":"10.1016/j.smim.2025.101965","DOIUrl":"10.1016/j.smim.2025.101965","url":null,"abstract":"<div><div>Emerging observations at the molecular, cellular, and organismal levels have unveiled critical roles for glycans in regulating a broad range of innate and adaptive immune cell processes. Through interactions with various families of glycan-binding proteins, including galectins, C-type lectins, and siglecs, glycans shape the nature, the fate and the function of immune cell types, modulating processes such as immune cell development, activation, differentiation, trafficking, exhaustion, and survival. Furthermore, dysregulated glycosylation pathways and altered glycan-binding receptor functions are associated with several pathological conditions, including infection, autoimmunity, and cancer. This special issue highlights the most recent updates and current challenges on the multifunctional roles of glycans and glycan-binding proteins in orchestrating, amplifying, or inhibiting immune responses. This collection seeks to enhance awareness of the significance of glycans in immunobiology and immunopathology from cellular, molecular, and evolutionary perspectives into clinical applications, underscoring their relevance as promising biomarkers and targets for designing novel immunotherapeutic approaches.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"78 ","pages":"Article 101965"},"PeriodicalIF":7.4,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144098465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing complement biomarkers for precision cancer care 利用补体生物标志物进行精准癌症治疗

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-05-15 DOI: 10.1016/j.smim.2025.101963

Houcine Hamidi , Idris Boudhabhay , Marie-Agnes Dragon-Durey

{"title":"Harnessing complement biomarkers for precision cancer care","authors":"Houcine Hamidi , Idris Boudhabhay , Marie-Agnes Dragon-Durey","doi":"10.1016/j.smim.2025.101963","DOIUrl":"10.1016/j.smim.2025.101963","url":null,"abstract":"<div><div>The tumor microenvironment (TME) consists of various immune and non-immune cells, along with proteins from different origins, and plays a crucial role in tumor development, treatment response, and patient prognosis. Complement system is a key player in the TME. It is a proteolytic cascade that generates cleavage fragments capable to activate cells through specific receptors or deposit on cells and tissues. This review summarizes current data on the complement system as a potential biomarker in cancer. Transcriptomic analyses have classified tumors based on the impact of complement gene expression on prognosis. Immunostaining provides insights into the expression and deposition of complement proteins and fragments in tumors and TME cells. In body fluids such as blood, measuring complement activation fragments and detecting anti-complement autoantibodies have identified non-invasive biomarkers relevant to certain cancer types. With the rise of complement-targeting therapies and new tools for analyzing the complement system in tumors and body fluids, it is time to define its role in cancer management. This includes its potential for cancer detection, staging, and potentially for treatment monitoring.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"78 ","pages":"Article 101963"},"PeriodicalIF":7.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches 通过假设驱动和假设生成方法揭示1型发作性睡病的病理生理学

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-05-14 DOI: 10.1016/j.smim.2025.101962

Sean A. Freeman , Ikram Ayoub , Yves Dauvilliers , Roland S. Liblau

{"title":"Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches","authors":"Sean A. Freeman , Ikram Ayoub , Yves Dauvilliers , Roland S. Liblau","doi":"10.1016/j.smim.2025.101962","DOIUrl":"10.1016/j.smim.2025.101962","url":null,"abstract":"<div><div>Narcolepsy type 1 (NT1) is a chronic orphan neurological sleep disorder characterized by the loss of hypocretin-producing neurons in the lateral hypothalamus, which play a crucial role in wakefulness. Given the genetic association with the <em>HLA-DQB1 * 06:02</em> allele and environmental links with the 2009 influenza pandemic, many lines of evidence point towards an immune mechanism, notably autoimmunity, underlying the disease pathophysiology. Autoreactive T cells are found in the blood of NT1 patients, and mouse models demonstrate their migratory capacity and contribution in the selective destruction of hypocretin-producing neurons. However, direct evidence for their role in human NT1 pathophysiology remains elusive. In complementing these findings, hypothesis-generating approaches—including multiparametric immune profiling, transcriptomic sequencing and large-scale proteomic of blood and cerebrospinal fluid—have uncovered promising new avenues into the immune system’s involvement in NT1. In this review, we explore the mechanisms driving NT1 pathogenesis, emphasizing both hypothesis-driven and hypothesis-generating approaches, and discuss potential future directions that could pave the way for targeted immunotherapies.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"78 ","pages":"Article 101962"},"PeriodicalIF":7.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Individual- and population-associated heterogeneity in vaccine-induced immune responses. The impact of inflammatory status and diabetic comorbidity 疫苗诱导免疫反应的个体和群体相关异质性。炎症状态和糖尿病合并症的影响

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-05-09 DOI: 10.1016/j.smim.2025.101964

Simone A. Joosten

引用次数: 0

Global aspects of celiac disease and food allergy 乳糜泻和食物过敏的全球视角

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-04-28 DOI: 10.1016/j.smim.2025.101961

Samagra Agrawal, Govind K. Makharia

引用次数: 0

The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy 免疫检查点抑制剂治疗后神经免疫相关不良事件的发病机制

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-04-27 DOI: 10.1016/j.smim.2025.101956

Magdalena Lerch , Sudarshini Ramanathan

{"title":"The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy","authors":"Magdalena Lerch , Sudarshini Ramanathan","doi":"10.1016/j.smim.2025.101956","DOIUrl":"10.1016/j.smim.2025.101956","url":null,"abstract":"<div><div>Cancer is a leading cause of morbidity and mortality worldwide. The development of immune checkpoint inhibitors (ICI) has revolutionised cancer therapy, and patients who were previously incurable can now have excellent responses. These therapies work by blocking inhibitory immune pathways, like cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), its ligand PD-L1, and lymphocyte activation gene 3 (LAG-3); which leads to increased anti-tumour immune responses. However, their use can lead to the development of immune-related adverse events (irAEs), which may result in severe disability, interruption of cancer therapy, and even death. Neurological autoimmune sequelae occur in 1–10 % of patients treated with ICIs and can be fatal. They encompass a broad spectrum of diseases, may affect the central and the peripheral nervous system, and include syndromes like encephalitis, cerebellitis, neuropathy, and myositis. In some cases, neurological irAEs can be associated with autoantibodies recognising neuronal or glial targets. In this review, we first describe the key targets in ICI therapy, followed by a formulation of irAEs and their clinical presentations, where we focus on neurological syndromes. We comprehensively formulate the current literature evaluating cell surface and intracellular autoantibodies, cytokines, chemokines, leukocyte patterns, other blood derived biomarkers, and immunogenetic profiles; and highlight their impact on our understanding of the pathogenesis of neurological irAEs. Finally, we describe therapeutic pathways and patient outcomes, and provide an overview on future aspects of ICI cancer therapy.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"78 ","pages":"Article 101956"},"PeriodicalIF":7.4,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0